A Phase I Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Napabucasin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sumitomo Dainippon Pharma
- 02 Feb 2018 Status changed from active, no longer recruiting to completed.
- 06 Mar 2017 Planned End Date changed from 1 May 2016 to 1 Nov 2016.
- 06 Mar 2017 Planned primary completion date changed from 1 May 2017 to 1 Nov 2017.